SCHEMBL30454240

SCHEMBL30454240

CC(C)(C)OC(=O)NCc1ccccc1CO

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 1/20 0.52
KDM4A O75164 1/20 0.51
NAMPT P43490 2/20 0.48
HDAC10 Q969S8 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
GAA P10253 1/20 0.44
RAB9A P51151 1/20 0.44
KMT2A Q03164 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA7 P43166 1/20 0.44
CA14 Q9ULX7 1/20 0.44
NQO2 P16083 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HDAC1 Q13547 2/20 0.44
MALT1 Q9UDY8 1/20 0.43
IDO1 P14902 1/20 0.43
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6874894 1.00 KCNA5 (0.52) KCNA5KDM4ANAMPTHDAC10HDAC6
SCHEMBL8018113 0.93 KCNA5 (0.56) KCNA5KDM4ANAMPTHDAC10HDAC6
SCHEMBL30159605 0.93 KCNA5 (0.56) KCNA5KDM4ANAMPTHDAC10HDAC6
SCHEMBL8254926 0.89 KCNA5 (0.61) KCNA5KDM4ANAMPTHDAC10HDAC6
SCHEMBL7257995 0.88 KCNA5 (0.50) KCNA5KDM4ANAMPTHDAC10HDAC6
SCHEMBL7654695 0.86 KCNA5 (0.54) KCNA5KDM4ANAMPTHDAC10HDAC6
SCHEMBL6924987 0.86 KCNA5 (0.51) KCNA5KDM4ANAMPTHDAC10HDAC6
SCHEMBL13656743 0.85 NQO2 (0.51) KCNA5KDM4ANAMPTHDAC10HDAC6
SCHEMBL18322375 0.85 KCNA5 (0.48) KCNA5KDM4ANAMPTHDAC10HDAC6
SCHEMBL30236239 0.85 KCNA5 (0.48) KCNA5KDM4ANAMPTHDAC10HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025094035-A1 TOLL-LIKE RECEPTOR AGONISTS AND CONJUGATES THEREOF PFIZER INC. (US) 2025-05-08 WO disclosed
EP-4440700-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION Gilead Sciences, Inc. (US) 2024-10-09 EP disclosed
US-12084467-B2 Therapeutic compounds for HIV virus infection GILEAD SCIENCES, INC. (US) 2024-09-10 US disclosed
US-20230203071-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. 2023-06-29 US disclosed
WO-2023102529-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. (US) 2023-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12084467-B2 Therapeutic compounds for HIV virus infection HAVCR2, MAVS, CD4 KCNA5 4700/4885KDM4A 2781/4885NAMPT 355/4885
US-20230203071-A1 THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION HAVCR2, MAVS, CD4 KCNA5 4700/4885KDM4A 2781/4885NAMPT 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.